Plain-English translation of NCT06287814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →This research study is testing whether a special blood test can detect tiny amounts of cancer DNA that might remain after surgery and chemotherapy for stage III colon cancer. Researchers want to see if this blood test — called a liquid biopsy — can predict which patients are at risk of cancer coming back, even before symptoms or imaging tests show a problem. If successful, this could help doctors decide whether patients need additional treatment or can be spared unnecessary therapy.
Right now, all patients with stage III colon cancer receive chemotherapy after surgery because about 25% of them will have their cancer return. However, this means about 75% of patients receive chemotherapy they may not have needed — causing unnecessary side effects. This study exists to see if a simple blood test could identify which patients actually need chemotherapy and which ones are already cured by surgery alone.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood samples taken at several time points: before your surgery, after your surgery, during your chemotherapy treatment, and at follow-up visits after treatment ends. You will continue to receive your regular cancer care as planned. The study team will use these blood samples to test whether they can detect cancer DNA and compare the results to your imaging scans and health outcomes over time. This is an observational study, meaning researchers are collecting information and samples to understand how the blood test works — you are not receiving an experimental medication.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
France